Cytokinetics Inc. is raising $33 million through a stock sale to fund clinical development of its lead products, including a heart failure drug that recently started a Phase I trial. (BioWorld Today)

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld International)

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld International)

Forging ahead with its lupus drug, Prestara, Genelabs Technologies Inc. has decided to conduct another Phase III trial, and likely will look for a development partner to help offset costs. (BioWorld Today)

Forging ahead with its lupus drug, Prestara, Genelabs Technologies Inc. has decided to conduct another Phase III trial, and likely will look for a development partner to help offset costs. (BioWorld Today)

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld Today)

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld Today)

Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)

Lower-than-expected sales from its flagship cancer drug, Avastin, eclipsed solid fourth-quarter and full-year earnings for Genentech Inc., and caused the company's shares to fall nearly 5 percent in early trading Wednesday. (BioWorld Today)